Elimination of Albumin-Bound Substances by MARS and Prometheus

Effect of Extracorporeal Liver Support by MARS and Prometheus on Albumin-Bound Substances in Acute-on-Chronic Liver Failure

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00407004

Enrollment

Registered

2006-12-04

Start date

2003-03-31

Completion date

2004-04-30

Last updated

2006-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Failure

Keywords

acute-on-chronic liver failure, MARS, Prometheus, bilirubin, bile acids, cytokines

Brief summary

This trial compares the efficacy of two artificial liver support systems, MARS (Molecular Adsorbents Recirculating System) and Prometheus (FPSA, Fractionated Plasma Separation and Adsorption), in removing albumin-bound substances such as bilirubin, bile acids, and cytokines.

Interventions

DEVICEMARS (Molecular Adsorbents Recirculating System)

DEVICEPrometheus (FPSA, Fractionated Plasma Separation and Adsorption)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* consecutive patients with acute-on-chronic liver failure (severe deterioration of chronic liver disease) unresponsive to standard medical treatment for \>=48 hours

Exclusion criteria

* arterial hypotension * extrahepatic malignancy

Design outcomes

Primary

Measure	Time frame
serum levels of albumin-bound substances	—

Secondary

Measure	Time frame
plasma clearance of albumin-bound substances	—

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026